The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have witnessed the achievements of convincing clinical benefits that feature the significantly prolonged overall survival (OS) of patients suffering from advanced non-small cell lung cancer (NSCLC), according to reports recently. Sensitivity to immunot...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xilin, Xu, Hanlin, Xue, Qianwen, Wen, Ruran, Jiao, Wenjie, Tian, Kaihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496027/
https://www.ncbi.nlm.nih.gov/pubmed/34620079
http://dx.doi.org/10.1186/s10020-021-00387-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496027/
https://www.ncbi.nlm.nih.gov/pubmed/34620079
http://dx.doi.org/10.1186/s10020-021-00387-z

Ejemplares similares